Tseng Fen-Yu, Lin Wen-Yuan, Li Chia-Ing, Li Tsai-Chung, Lin Cheng-Chieh, Huang Kuo-Chin
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan; School of Medicine, China Medical University, Taichung, Taiwan; Graduate Institute of Clinical Medicine Science, China Medical University, Taichung, Taiwan.
PLoS One. 2015 Apr 1;10(4):e0122955. doi: 10.1371/journal.pone.0122955. eCollection 2015.
The association between subclinical hypothyroidism (SCH) and cancer mortality is seldom discussed.
A total of 115,746 participants without thyroid disease history, aged 20 and above, were recruited from four nationwide health screening centers in Taiwan from 1998 to 1999. SCH was defined as a serum thyroid-stimulating hormone (TSH) level of 5.0-19.96 mIU/L with normal total thyroxine concentrations. Euthyroidism was defined as a serum TSH level of 0.47-4.9 mIU/L. Cox proportional hazards regression analyses were used to estimate the relative risks (RRs) of death from cancer for adults with SCH during a 10-year follow-up period.
Among 115,746 adults, 1,841 had SCH (1.6%) and 113,905 (98.4%) had euthyroidism. There were 1,532 cancer deaths during the 1,034,082 person-years follow-up period. Adjusted for age, gender, body mass index, diabetes, hypertension, dyslipidemia, smoking, alcohol drinking, betel nut chewing, physical activity, income, and education level, the RRs (95% confidence interval) of cancer deaths among subjects with SCH versus euthyroid subjects were 1.51 (1.06 to 2.15). Cancer site analysis revealed a significant increased risk of bone, skin and breast cancer among SCH subjects (RR 2.79, (1.01, 7.70)). The risks of total cancer deaths were more prominent in the aged (RR 1.71, (1.02 to 2.87)), in females (RR 1.69 (1.08 to 2.65)), and in heavy smokers (RR 2.24, (1.19 to 4.21)).
Subjects with SCH had a significantly increased risk for cancer mortality among adult Taiwanese. This is the first report to demonstrate the association between SCH and cancer mortality.
亚临床甲状腺功能减退(SCH)与癌症死亡率之间的关联鲜有讨论。
1998年至1999年期间,从台湾四个全国性健康筛查中心招募了115746名年龄在20岁及以上且无甲状腺疾病史的参与者。SCH定义为血清促甲状腺激素(TSH)水平为5.0 - 19.96 mIU/L且总甲状腺素浓度正常。甲状腺功能正常定义为血清TSH水平为0.47 - 4.9 mIU/L。采用Cox比例风险回归分析来估计SCH成年人在10年随访期内癌症死亡的相对风险(RRs)。
在115746名成年人中,1841人患有SCH(1.6%),113905人(98.4%)甲状腺功能正常。在1034082人年的随访期内有1532例癌症死亡。在调整了年龄、性别、体重指数、糖尿病、高血压、血脂异常、吸烟、饮酒、嚼槟榔、身体活动、收入和教育水平后,SCH患者与甲状腺功能正常患者相比,癌症死亡的RRs(95%置信区间)为1.51(1.06至2.15)。癌症部位分析显示,SCH患者中骨癌、皮肤癌和乳腺癌的风险显著增加(RR 2.79,(1.01,7.70))。总癌症死亡风险在老年人(RR 1.71,(1.02至2.87))、女性(RR 1.69(1.08至2.65))和重度吸烟者(RR 2.24,(1.19至4.21))中更为突出。
台湾成年人中,患有SCH的个体癌症死亡率风险显著增加。这是首次证明SCH与癌症死亡率之间关联的报告。